A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 1300
Summary
- Conditions
- Plasma Cell Myeloma
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Duration per participant is 2.5 years
Duration per participant is 2.5 years
Tracking Information
- NCT #
- NCT04458831
- Collaborators
- Not Provided
- Investigators
- Study Director: Clinical Sciences & Operations Sanofi